EDAP TMS S.A. — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022; filed April 7, 2023. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP and reported in euros unless stated otherwise.
Business context
EDAP develops, manufactures, markets and distributes minimally invasive medical devices, principally for urological conditions. Its divisions are HIFU (including Focal One), ESWL lithotripters and Distribution (third-party products including ExactVu and lasers). The company’s strategy emphasizes expanding Focal One adoption in the United States and developing HIFU uses beyond prostate cancer.
Financial performance and liquidity
| Metric (€ millions, except per-share data) | 2022 | 2021 |
|---|---|---|
| Revenue | 55.1 | 44.1 |
| Gross profit | 24.2 | 18.4 |
| Gross margin | 43.9% | 41.8% |
| Operating income (loss) | (4.3) | (1.6) |
| Net income (loss) | (2.9) | 0.7 |
| Basic and diluted EPS | (€0.09) | €0.02 |
| Cash from operating activities | (3.0) | 4.4 |
| Cash from investing activities | (2.4) | (1.6) |
| Cash from financing activities | 21.7 | 20.3 |
| Cash and cash equivalents at year-end | 63.1 | 47.2 |
Revenue grew 25.1%. Cost of sales was €30.9 million, and operating expenses rose 42.0% to €28.5 million, reflecting expansion spending, particularly U.S. sales and marketing. The reported 2022 net loss included a €1.9 million foreign-exchange gain; 2021 included a €2.4 million gain.
Revenue by division: HIFU €15.6 million (up 57.7%); ESWL €11.6 million (up 5.0%); Distribution €27.9 million (up 20.6%). HIFU sold 15 Focal One units, including 13 in the U.S., versus seven units in 2021. Distribution sold 47 ExactVu units versus 28. U.S. sales rose to €15.0 million from €5.5 million; Asia contributed €17.9 million.
Liquidity and debt: Year-end cash was €63.1 million, while operating cash flow was negative, mainly reflecting a €4.3 million working-capital increase associated with higher inventory and receivables. Long-term debt was €5.2 million and short-term borrowings €1.8 million. The company also reported €0.5 million of finance-lease liabilities and €1.8 million of operating-lease obligations. Financing cash flow included €22.0 million of net proceeds from a September 2022 ADS offering. Management stated working capital was sufficient for present needs, while noting future cash flow may fluctuate.
Material changes versus 2021
- Revenue increased across all three divisions, led by U.S. Focal One equipment sales and growth in Distribution.
- Gross margin improved to 43.9% from 41.8%, but higher R&D, selling and marketing, and administrative costs increased the operating loss to €4.3 million from €1.6 million.
- Net income of €0.7 million became a net loss of €2.9 million. The prior-year result included a €0.6 million deferred-tax benefit; both years’ results were affected by foreign-exchange gains.
- Operating cash flow shifted from €4.4 million generated to €3.0 million used, despite higher revenue.
- Cash increased by €16.0 million, supported substantially by the 2022 equity offering. Shareholders’ equity rose to €71.6 million from €50.1 million.
Outlook, commentary and principal risks
- Management expects R&D spending to increase to approximately 11.9% of revenue beginning in 2023 and expects selling and marketing expenses to rise as U.S. HIFU expansion accelerates. The filing provides no specific revenue or earnings guidance.
- CMS’s 2023 reimbursement rule, effective January 1, 2023, raised the U.S. hospital payment classification for HIFU; the filing estimates average Medicare facility reimbursement of approximately $8,500 per procedure, compared with approximately $4,500 previously. Broader private-insurer coverage and sustained physician and patient adoption remain uncertain.
- HIFU remains subject to clinical, regulatory and market-acceptance risks. France’s decision on definitive HIFU reimbursement was expected in 2023. A Phase III trial for deep infiltrating endometriosis was approved in France; broader indications will require additional investment and evidence.
- Other key risks include reliance on a single manufacturing facility and certain single-source suppliers, including renegotiation of a key HIFU ultrasound-component agreement after substantial price increases; inflation and supply-chain disruption; competition; reimbursement changes; foreign-exchange exposure; and reliance on distributors.
- EDAP reported no outstanding foreign-exchange hedging instruments at year-end. It closed its Moscow representative office; Russia represented 1.5% of 2022 revenue. The filing reports no outstanding legal proceedings and no dividends, with none anticipated in the foreseeable future.
- Controls: Management and KPMG concluded internal control over financial reporting was ineffective at December 31, 2022 because of material weaknesses at the U.S. subsidiary involving vendor invoices, sales invoices and inventory counts. Management reported no resulting material misstatement or restatement and described remediation hiring and control work. KPMG issued an adverse opinion on internal controls but an unqualified opinion on the consolidated financial statements.
- Subsequent event: Ryan Rhodes was appointed CEO effective May 1, 2023, with Marc Oczachowski continuing as Board chair. The company accelerated vesting of certain Oczachowski awards and was evaluating related 2023 costs.
Investor verification priorities
- Confirm whether U.S. Focal One placements and procedure volumes are translating into recurring treatment revenue, and whether reimbursement coverage is broadening beyond Medicare.
- Track cash burn and working-capital needs, especially inventory, receivables and the extent to which expansion is funded by operations versus equity financing.
- Assess the trajectory of operating expenses against HIFU growth, including expected R&D and U.S. selling and marketing spending.
- Monitor remediation and auditor assessments of the U.S. subsidiary’s material weaknesses, and whether controls over sales, purchasing and inventory become effective.
- Review supplier alternatives and the outcome of the key HIFU component price renegotiation, as well as compliance timelines under the EU Medical Device Regulation.
- Distinguish operating performance from foreign-exchange effects and monitor dilution from share offerings, options and free-share awards.